Opinion|Videos|September 13, 2024
Similarities and Differences among Bispecifics: BCMA vs non-BCMA
Medical experts examine differences and similarities in the referral process and treatment protocols for non–BCMA-targeted vs BCMA-targeted bispecific therapies, including aspects like step-up dosing and premedication.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Is the process different/similar for patients who might be receiving non–BCMA-targeted bispecific vs BCMA-targeted bispecific?
Review any differences/similarities between bispecifics (non-BCMA vs BCMA) for step-up dosing, premedication/prophylaxis, etc.
Advertisement
Related to this article
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
Longer follow-up is needed for the phase 3 MIDAS trial to determine the impact of MRD conversion on progression-free survival and overall survival.
The FDA cleared TriSalus’s TriNav Advance device, which extends the SmartValve-based drug delivery technology to improve tumor penetration during liver embolization.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
MELT-MM Regimen Yields Responses in Relapsed/Refractory Multiple Myeloma
5